Page last updated: 2024-09-05

sorafenib and Anemia

sorafenib has been researched along with Anemia in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Choe, SW; Kim, MJ; Kim, YH; Lee, YJ; P Oh, S; Sprecher, D	1
Greil, R; Grundbichler, M; Kappacher, A; Mlineritsch, B; Moik, M; Ressler, S; Rosenlechner, S	1

Other Studies

2 other study(ies) available for sorafenib and Anemia

Article	Year
Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia. Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:6 Topics: Activin Receptors, Type I; Activin Receptors, Type II; Administration, Oral; Administration, Topical; Anemia; Angiogenesis Inhibitors; Animals; Arteriovenous Malformations; Disease Models, Animal; Erlotinib Hydrochloride; Gastrointestinal Hemorrhage; Hemoglobins; Image Processing, Computer-Assisted; Indazoles; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Skin; Sorafenib; Sulfonamides; Sulfones; Telangiectasia, Hereditary Hemorrhagic; Tyrosine; Vascular Endothelial Growth Factor A; Wound Healing	2017
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer. Oncology, 2011, Volume: 80, Issue:1-2 Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Thrombocytopenia	2011

Article

Year

Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.

Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:6

Topics: Activin Receptors, Type I; Activin Receptors, Type II; Administration, Oral; Administration, Topical; Anemia; Angiogenesis Inhibitors; Animals; Arteriovenous Malformations; Disease Models, Animal; Erlotinib Hydrochloride; Gastrointestinal Hemorrhage; Hemoglobins; Image Processing, Computer-Assisted; Indazoles; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Skin; Sorafenib; Sulfonamides; Sulfones; Telangiectasia, Hereditary Hemorrhagic; Tyrosine; Vascular Endothelial Growth Factor A; Wound Healing

2017

Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.

Oncology, 2011, Volume: 80, Issue:1-2

Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Thrombocytopenia

2011